The SOLVE-CRT trial evaluated patients indicated for CRT who were previously untreatable or considered high risk upgrades. The study found that the WiSE System, the only leadless left ventricular endocardial pacing (LVEP) device, can safely deliver CRT.
- 16.4% improvement in left ventricular end systolic volume (LVESV), in heart failure patients in the first 6-months.
- 80.9% of patients had no serious procedure or device-related complications in the first 6-months.